Axsome Therapeutics Inc’s recent filing unveils that its Officer Herriot Tabuteau acquired Company’s shares for reported $6.81 million on Nov 04 ’25. In the deal valued at $134.93 per share,50,459 shares were bought.
Then, Herriot Tabuteau bought 91,705 shares, generating $12,448,954 in total proceeds.
Before that, TABUTEAU HERRIOT sold 19,220 shares. Axsome Therapeutics Inc shares valued at $2,309,667 were divested by the Chief Executive Officer at a price of $120.17 per share. As a result of the transaction, TABUTEAU HERRIOT now holds 7,229 shares, worth roughly $0.98 million.
B. Riley Securities initiated its Axsome Therapeutics Inc [AXSM] rating to a Buy in a research note published on October 01, 2025; the price target was $179. Oppenheimer started covering the stock on June 03, 2025. It rated AXSM as “an Outperform”.
Price Performance Review of AXSM
On Tuesday, Axsome Therapeutics Inc [NASDAQ:AXSM] saw its stock fall -0.60% to $134.93. Over the last five days, the stock has gained 1.06%. Axsome Therapeutics Inc shares have risen nearly 51.56% since the year began. Nevertheless, the stocks have risen 59.47% over the past one year. While a 52-week high of $139.13 was reached on 02/21/25, a 52-week low of $75.56 was recorded on 01/10/25.
Levels Of Support And Resistance For AXSM Stock
The 24-hour chart illustrates a support level at 132.26, which if violated will result in even more drops to 129.59. On the upside, there is a resistance level at 136.85. A further resistance level may holdings at 138.77.
How much short interest is there in Axsome Therapeutics Inc?
A steep rise in short interest was recorded in Axsome Therapeutics Inc stocks on 2025-10-15, dropping by 14115.0 shares to a total of 3.44 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-15 was 3.45 million shares. There was a decline of -0.41%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on April 07, 2025 when Jefferies began covering the stock and recommended ‘”a Buy”‘ rating along with a $200 price target.
